Page 6 - Haematologica April 2020

haematologica Journal of the Ferrata Storti Foundation
951 Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups Caoimhe Egan et al.
Myelodysplastic Syndrome
961 Thrombomodulin-expressing monocytes are associated with low-risk features in myelodysplastic syndromes and dampen excessive immune activation
Nathalie van Leeuwen-Kerkhoff et al.
Chronic Myeloid Leukemia
972 Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells
Harish Kumar et al.
Acute Myeloid Leukemia
987 Mesenchymal stromal cells confer chemoresistance to myeloid leukemia blasts through Side Population functionality and ABC transporter activation
Laetitia Boutin et al.
999 Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia Vijaya Pooja Vaikari et al.
Acute Lymphoblastic Leukemia
1013 Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen
Mirko Kroll et al.
Non-Hodgkin Lymphoma
1021 EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma
Shao Xie et al.
1032 Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
Anna Vidal-Crespo et al.
Chronic Lymphocytic Leukemia
1042 HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
Valentina Griggio et al.
Plasma Cell Disorders
1055 Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma Aneta Mikulasova et al.
1067 Fractures and survival in multiple myeloma: results from a population-based study Sigrun Thorsteinsdottir et al.
1074 First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
Alessandra Larocca et al.
Platelet Biology & its Disorders
1081 The role of neuraminidase 1 and 2 in glycoprotein Ibα-mediated integrin αIIbβ3 activation Dianne E. van der Wal et al.
Histiocytic DIsordes
Haematologica 2020; vol. 105 no. 4 - April 2020 http://www.haematologica.org/